Christopher N. Greene, PhD Newborn Screening and Molecular Biology Branch, Division of Laboratory...
-
Upload
sammy-loller -
Category
Documents
-
view
219 -
download
3
Transcript of Christopher N. Greene, PhD Newborn Screening and Molecular Biology Branch, Division of Laboratory...
Christopher N. Greene, PhD
Newborn Screening and Molecular Biology Branch,
Division of Laboratory Sciences
NCEH, CDC
Tuesday, 9th July 2013
Assay Quality Considerations
National Center for Environmental Health
U.S. Centers for Disease Control and Prevention
Molecular Testing
Testing Parameters Examples
Target Analyte Genetic Mutations, Gene Dosage
Platform PCR, qPCR, bead arrays, Fluorescent Probe, DNA Sequencers
Complexity Single- or multi-plex of single nucleotides, Laboratory Developed Test, ASRs, FDA-approved, Gene Sequencing, Next-Gen Sequencing
Multiple molecular assays have been developed for screening procedures. These assays vary on their complexity, the target analyte, as well as the platform used for analysis.
Molecular Testing
When Adopting a New Test Required Evidence
Test Development - LDT Accuracy, precision, reproducibility, sensitivity, specificity, robustness
Test Validation - ASR Clinical and analytic performance and test limitations
Test Verification – FDA approved Identify samples or reference materials of known quantitative or qualitative values to verify test performance
Molecular tests require verification or validation of assay results. Level of evidence required is related to the type of assay, i.e. laboratory developed test, analyte specific reagents or FDA approved assays.
Laboratory Regulatory and Accreditation Guidelines
US Food and Drug Administration (FDA):
approves kits and reagents for use in clinical testing
Clinical Laboratory Improvement Amendments (CLIA): Regulations passed by Congress1988 to establish quality
standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test was performed
College of American Pathologists (CAP): Molecular Pathology checklist
State Specific Regulations
Testing Parameters
Accuracy
Sensitivity
Specificity
Precision
Limit of Detection
Range
Reproducibility
Robustness
Definitions
• Accuracy: Agreement between test result and the “true” result– Comparison of results between new method
and a reference method– Results of new method on certified reference
materials
• Sensitivity: Ability to obtain positive results in concordance with a positive result of a reference method – can the test detect a positive result
Definitions
• Specificity: Ability to obtain a negative result for a qualitative test in concordance with reference method
• Precision: Measure of random error in quantitative tests, the closeness of agreement usually expressed as standard deviation of CV
Definitions
• Limit of Detection: Lowest amount of analyte that is distinguishable from background or a negative control
• Range: Range of test values expected for the test population. For quantitative, high and low range of target, for qualitative, possible detectable alleles of the assay
Definitions
• Reproducibility: Equivalent to precision for qualitative and semi-quantitative tests. Can be used to indicate with-in or between run agreement of test results
• Robustness: Test precision, given small, deliberate changes in test conditions (e.g. incubation times, temperature variation)
Pre-Validation
Choose and evaluate assay methodology
Determining analytic performance of an assay involves:
Reviewing professional guidelines and relevant literature
Stringent design/analysis of primers and probes
Quality and quantity of extracted nucleic acid
Appropriate platform for the test
Availability of controls or calibrators
Optimization of amplification and detection
Verifying Assay Specifications
• Demonstrate that laboratory can obtain specifications comparable to manufacturer– Accuracy– Precision– Reportable Results
• Applies to unmodified FDA-approved tests
• Verify appropriate test results for population
• May require matrix-appropriate materials during verification
Assay Validation
• Performance characteristics of laboratory developed tests
• Reagents that are the components of a test that is created without regulatory approval – ASR
• Use of FDA-approved tests that have been modified for the testing procedure
Establish that the assay fulfills its intended use with the appropriate sample type and population
Modified FDA Test
• Alteration of any assay step or analyte for the test that may affect performance
• Changes could include:– Type or concentration of specimen– Storage specifications– Extraction method– Amplification parameters or platforms– Use of test for other purposes
Assay Validation
Required for: New testing methodology Assay modification – includes cross-checks for different
makes/models of instrumentation
Applies to: Modified FDA assays Laboratory Developed methods
Controls for Each Run
Appropriate positive and negative controls should be included for each run of specimens being tested
Molecular Assay Controls
Positive controls: Inhibitors Component failure Interpretation of results Sources:
Residual positive DBSPT samplesQC materials through purchase or exchange
Negative controls: Nucleic acid contamination
Common Molecular Assay Problems and Trouble
Shooting
Temperature errors
Template/Sequence
PCR inhibitors
Buffers
Bad dNTPs
Bad primers
Bad enzyme
Critical Molecular Assay Components
Nucleic Acids: Prepare aliquots appropriate to workflow to limit freeze-thaw cycles Primers and probes dNTPs Genomic DNA
4-8°C: Up to one year-20°C: Up to seven years
Enzymes Benchtop coolers recommended
Fluorescent reporters Limit exposure to light Amber storage tubes or wrap in shielding (foil)
Positive Controls
Ideally should represent each target allele used in each run
May not be feasible when:
Highly multiplex genotypes possible
Systematic rotation of different alleles as positives
Rare alleles
Heterozygous or compound heterozygous specimens
Positive Controls
Assays based on presence or absence of product Internal positive amplification controls to distinguish true
negative from false due to failure of DNA extraction or PCR amplification
PCR amplification product of varying length Specimens representing short and long amplification
products to control for differential amplification
Quantitative PCR Controls should represent more than one concentration
Control copy levels should be set to analytic cut-offs
Quantitative PCR Controls
• Contamination controls• Calibration control with reliable low
limit of quantification• Measures for consistency, especially
for DBS• Measure of DNA quality – internal
control
False Negative: ADO
Allele drop-out (ADO): the failure of a molecular test to amplify or detect one or more alleles
Potential causes: DNA template concentration
• Incomplete cell lysis • DNA degradation
Non-optimized assay conditions Unknown polymorphisms in target sites Reagent component failure
Major concern for screening laboratories Confirmation of mutation inheritance in families is not an
option
DNA Degradation
Lane 1 + 7:1kb size standard ladder
Lane 2:100ng control genomic DNA
Lanes 3-5:Crude cell lysates
Question?
How can you control for presence
of sufficient amount/quality of
DNA for a PCR based test in a NBS
lab?
PCR Amplification Controls
• Allele-specific amplification• Are there problems with this assay?• What additional controls would be useful?
Allele 1 + 2 Allele 2 Allele 1 Reference Negative
PCR with Internal Controls
Tetra-primer ARMS-PCR
Simultaneous amplification of:
Positive amplification control
Mutation allele
Reference allele
Alternative to tetra-primer ARMS is to include an additional primer set to amplify a different control sequence
Allele Drop-out in PCR Testing
ggacatgatGcactacatgctccaaggtagtggagCgtgatgtacgaggttccat
5’
ggacatgatGcactacatgctccaaggtagtggagcctgtactaCgtgatgtacgaggttccat
5’
Allele Drop-out in PCR Testing
SNP in primer site
ggacatgatGcGctacatgctccaaggtagtggaggatgtacgaggttccat
5’
ggacatgatGcGctacatgctccaaggtagtggag
Cgtgatgtacgaggttccat5’
Cgt
False Negatives: Deletions
A
G
Reverse Primer
Forward Primer
Reverse Primer
Forward Primer
False Negatives: Deletions
A
G
Reverse Primer
Forward Primer
Reverse Primer
Forward Primer
Deletion
False Positives
Potential causes:
Non-optimized assay conditions
Unknown polymorphisms in target sites
Gene duplications
Oligonucleotide mis-priming at related sequences
Psuedogenes or gene families
Oligonucleotide concentrations too high
Nucleic acid cross-contamination
How Many Samples?
• New test or to replace an old test?• How is the test to be used?• What performance criteria are most
important?• How available are appropriate samples?
• For screening: daily load vs. weekly load vs. monthly load – it depends
It depends…
CLSI Evaluation Protocols recognized by FDA as Consensus
Standards• EP5-A2: Evaluation of Precision Performance of
Quantitative Measurement Methods• EP9-A2: Method Comparison and Bias Estimation
Using Patient Samples• EP10-A2: Preliminary Evaluation of Quantitative
Clinical Methods• EP12-A User Protocol for Evaluation of Qualitative
Test Performance• EP15-A2: User Demonstration of Performance for
Precision and Accuracy
Molecular Assay Proficiency Testing Material Sources
CDC NSQAP
UKNEQS
EuroGentest
CAP
Maine Molecular
SeraCare
Corielle
ECACC
In-house samples
Round-robin with other NBS laboratories
Professional Guidelines
American College of Medical Genetics (ACMG) Standards and Guidelines for Clinical Genetics Laboratories
Clinical and Laboratory Standards Institute (CLSI) MM01-A2: Molecular Diagnostic Methods for Genetic Diseases
MM13-A: Collection, Transport, Preparation, and Storage of Specimens for Molecular Methods
MM14-A: Proficiency Testing (External Quality Assessment) for Molecular Methods
MM17-A: Verification and Validation of Multiplex Nucleic Acid Assays
MM19-P: Establishing Molecular Testing in Clinical Laboratory Environments
Additional Sources